ApolloBio Corporation
http://www.apollobio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ApolloBio Corporation
Finance Watch: Structure Launches Third And Largest US Biopharma IPO Of 2023
Public Company Edition: Structure Therapeutics’ upsized initial public offering raises $161.1m, surpassing proposed terms for up to $134.3m. Also, Pliant capitalizes on good data with a $287.5m follow-on offering, while Magenta seeks strategic alternatives and Instil reveals more job cuts.
Inovio Abandons Lassa, MERS Vaccines Shortly After Ending COVID-19 Booster Work
Two clinical-stage vaccine candidates for Lassa Fever and MERS, funded by CEPI, are being discontinued, but Inovio will continue its focus on DNA medicines for HPV-related conditions and cancer.
Deal Watch: AbbVie Partners With Gedeon Richter In Neuropsychiatry
Seeing strong sales with legacy Allergan’s Vraylar, AbbVie teams with Gedeon Richter on novel dopamine receptor modulators. AB Studio, CR Biopharma partner on COVID-19 neutralizing antibody.
Tech Transfer Roundup: Novo Nordisk Foundation, Broad Institute Team On Genomic Drivers Of Disease
$47.5m partnership between the foundation and Broad researchers will mine genetic data for insights into disease mechanisms. MD Anderson, Nuvectis each unveil multiple new tie-ups.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice